Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To determine whether the risk of adverse cardiovascular (CV) outcomes associated with
diabetes differs in patients with low and preserved ejection fraction (EF) heart failure
(HF).